Virulence determinants of West Nile virus

How can these be used for vaccine design?

Jaclyn A. Kaiser, Tian Wang, Alan Barrett

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

West Nile virus (WNV), a neurotropic mosquito-borne flavivirus, has become endemic in the USA and parts of Europe since 1999. There is no licensed WNV vaccine for humans. Considering the robust immunity from immunization with live, attenuated vaccines, a live WNV vaccine is an ideal platform for disease control. Animal and mosquito studies have identified a number of candidate attenuating mutations, including the structural proteins premembrane/membrane and envelope, and the nonstructural proteins NS1, NS2A, NS3, NS4A, NS4B and NS5, and the 3′ UTR. Many of the mutations that have been examined attenuate WNV using different mechanisms, thus providing a greater understanding of WNV virulence while also identifying specific mutations as candidates to include in a WNV live vaccine.

Original languageEnglish (US)
Pages (from-to)283-295
Number of pages13
JournalFuture Virology
Volume12
Issue number5
DOIs
StatePublished - May 1 2017

Fingerprint

West Nile Virus Vaccines
West Nile virus
Virulence
Vaccines
Culicidae
Mutation
Flavivirus
Attenuated Vaccines
3' Untranslated Regions
Immunity
Immunization
Membrane Proteins
Proteins

Keywords

  • attenuation
  • flavivirus
  • live attenuated vaccine
  • virulence
  • West Nile virus

ASJC Scopus subject areas

  • Virology

Cite this

Virulence determinants of West Nile virus : How can these be used for vaccine design? / Kaiser, Jaclyn A.; Wang, Tian; Barrett, Alan.

In: Future Virology, Vol. 12, No. 5, 01.05.2017, p. 283-295.

Research output: Contribution to journalReview article

@article{2540f675cf564bfbbe1f12089e40f5ee,
title = "Virulence determinants of West Nile virus: How can these be used for vaccine design?",
abstract = "West Nile virus (WNV), a neurotropic mosquito-borne flavivirus, has become endemic in the USA and parts of Europe since 1999. There is no licensed WNV vaccine for humans. Considering the robust immunity from immunization with live, attenuated vaccines, a live WNV vaccine is an ideal platform for disease control. Animal and mosquito studies have identified a number of candidate attenuating mutations, including the structural proteins premembrane/membrane and envelope, and the nonstructural proteins NS1, NS2A, NS3, NS4A, NS4B and NS5, and the 3′ UTR. Many of the mutations that have been examined attenuate WNV using different mechanisms, thus providing a greater understanding of WNV virulence while also identifying specific mutations as candidates to include in a WNV live vaccine.",
keywords = "attenuation, flavivirus, live attenuated vaccine, virulence, West Nile virus",
author = "Kaiser, {Jaclyn A.} and Tian Wang and Alan Barrett",
year = "2017",
month = "5",
day = "1",
doi = "10.2217/fvl-2016-0141",
language = "English (US)",
volume = "12",
pages = "283--295",
journal = "Future Virology",
issn = "1746-0794",
publisher = "Future Medicine Ltd.",
number = "5",

}

TY - JOUR

T1 - Virulence determinants of West Nile virus

T2 - How can these be used for vaccine design?

AU - Kaiser, Jaclyn A.

AU - Wang, Tian

AU - Barrett, Alan

PY - 2017/5/1

Y1 - 2017/5/1

N2 - West Nile virus (WNV), a neurotropic mosquito-borne flavivirus, has become endemic in the USA and parts of Europe since 1999. There is no licensed WNV vaccine for humans. Considering the robust immunity from immunization with live, attenuated vaccines, a live WNV vaccine is an ideal platform for disease control. Animal and mosquito studies have identified a number of candidate attenuating mutations, including the structural proteins premembrane/membrane and envelope, and the nonstructural proteins NS1, NS2A, NS3, NS4A, NS4B and NS5, and the 3′ UTR. Many of the mutations that have been examined attenuate WNV using different mechanisms, thus providing a greater understanding of WNV virulence while also identifying specific mutations as candidates to include in a WNV live vaccine.

AB - West Nile virus (WNV), a neurotropic mosquito-borne flavivirus, has become endemic in the USA and parts of Europe since 1999. There is no licensed WNV vaccine for humans. Considering the robust immunity from immunization with live, attenuated vaccines, a live WNV vaccine is an ideal platform for disease control. Animal and mosquito studies have identified a number of candidate attenuating mutations, including the structural proteins premembrane/membrane and envelope, and the nonstructural proteins NS1, NS2A, NS3, NS4A, NS4B and NS5, and the 3′ UTR. Many of the mutations that have been examined attenuate WNV using different mechanisms, thus providing a greater understanding of WNV virulence while also identifying specific mutations as candidates to include in a WNV live vaccine.

KW - attenuation

KW - flavivirus

KW - live attenuated vaccine

KW - virulence

KW - West Nile virus

UR - http://www.scopus.com/inward/record.url?scp=85019604822&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019604822&partnerID=8YFLogxK

U2 - 10.2217/fvl-2016-0141

DO - 10.2217/fvl-2016-0141

M3 - Review article

VL - 12

SP - 283

EP - 295

JO - Future Virology

JF - Future Virology

SN - 1746-0794

IS - 5

ER -